MiNK Therapeutics, Inc. (NASDAQ:INKT – Get Free Report)’s share price traded up 2.4% during mid-day trading on Wednesday. The company traded as high as $12.98 and last traded at $12.55. 61,095 shares traded hands during trading, an increase of 310% from the average session volume of 14,908 shares. The stock had previously closed at $12.26.
Analysts Set New Price Targets
A number of equities research analysts have commented on the stock. Weiss Ratings raised shares of MiNK Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, July 6th. Zacks Research cut shares of MiNK Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, August 12th. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $35.00.
Get Our Latest Analysis on INKT
MiNK Therapeutics Stock Down 1.6%
MiNK Therapeutics (NASDAQ:INKT – Get Free Report) last posted its earnings results on Thursday, August 13th. The company reported ($0.62) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.02). Analysts predict that MiNK Therapeutics, Inc. will post -2.48 earnings per share for the current year.
MiNK Therapeutics Company Profile
MiNK Therapeutics, Inc is a clinical-stage biotechnology company focused on developing allogeneic invariant natural killer T (iNKT) cell therapies for the treatment of cancer. Its approach is designed to use the immune system’s natural ability to recognize and attack tumors while potentially enabling an off-the-shelf cell therapy model.
The company’s lead product candidate is agenT-797, an allogeneic iNKT cell therapy being studied in patients with advanced solid tumors. MiNK has also evaluated agenT-797 in combination with other cancer treatments, including immune checkpoint inhibitors and cellular therapies, with the goal of improving responses in cancers that may be difficult to treat with existing approaches.
MiNK Therapeutics was established to advance iNKT-based immunotherapies and conducts its development activities through clinical research and collaborations in oncology.
Further Reading
- Five stocks we like better than MiNK Therapeutics
- AST SpaceMobile’s BlueBird Progress Comes With Several Risks Still Unresolved
- Time to Nibble on MCD Stock After it Enters Oversold Territory?
- McCormick Stock Trades Cheap, Offers Dividend Growth and Unilever Deal Upside
- Corning and AT&T’s $3 Billion Fiber Deal Reveals Where AI Spending Goes Next
Receive News & Ratings for MiNK Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MiNK Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
